rs121913648
Variant summary
Our verdict is Pathogenic. The variant received 13 ACMG points: 13P and 0B. PM1PM2PM4_SupportingPP5_Very_Strong
The NM_000257.4(MYH7):c.4850_4852delAGA(p.Lys1617del) variant causes a disruptive inframe deletion change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000257.4 disruptive_inframe_deletion
Scores
Clinical Significance
Conservation
Publications
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 13 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| MYH7 | NM_000257.4 | c.4850_4852delAGA | p.Lys1617del | disruptive_inframe_deletion | Exon 34 of 40 | ENST00000355349.4 | NP_000248.2 | |
| MYH7 | NM_001407004.1 | c.4850_4852delAGA | p.Lys1617del | disruptive_inframe_deletion | Exon 33 of 39 | NP_001393933.1 | ||
| MHRT | NR_126491.1 | n.374_376delTTC | non_coding_transcript_exon_variant | Exon 3 of 6 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| MYH7 | ENST00000355349.4 | c.4850_4852delAGA | p.Lys1617del | disruptive_inframe_deletion | Exon 34 of 40 | 1 | NM_000257.4 | ENSP00000347507.3 | ||
| MYH7 | ENST00000713768.1 | c.4850_4852delAGA | p.Lys1617del | disruptive_inframe_deletion | Exon 34 of 41 | ENSP00000519070.1 | ||||
| MYH7 | ENST00000713769.1 | c.4850_4852delAGA | p.Lys1617del | disruptive_inframe_deletion | Exon 33 of 39 | ENSP00000519071.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
MYH7-related skeletal myopathy Pathogenic:3Other:1
- -
- -
Most common recurrent pathogenic variant -
- -
not provided Pathogenic:2
In-frame deletion of 1 amino acid in a non-repeat region; In silico analysis supports a deleterious effect on protein structure/function; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 27081534, 24664454, 24300783, 15322983, 27387980, 29660325, 31130284, 32833721, 25214167, 33298082, 31069529) -
- -
Hypertrophic cardiomyopathy Pathogenic:1
This variant, c.4850_4852del, results in the deletion of 1 amino acid(s) of the MYH7 protein (p.Lys1617del), but otherwise preserves the integrity of the reading frame. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individuals with autosomal dominant early-onset Laing distal myopathy (PMID: 15322983, 16103042, 24300783, 24664454, 27387980). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 190401). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. For these reasons, this variant has been classified as Pathogenic. -
Cardiovascular phenotype Pathogenic:1
The c.4850_4852delAGA variant (also known as p.K1617del) is located in coding exon 32 of the MYH7 gene. This variant results from an in-frame AGA deletion at nucleotide positions 4850 to 4852. This results in the in-frame deletion of a lysine at codon 1617. This variant was reported in multiple individuals with features consistent with skeletal myopathy myopathy, and segregated with disease in families. One individual with skeletal myopathy was also reported to have dilated cardiomyopathy (Meredith C. et al. Am. J. Hum. Genet. 2004 Oct;75(4):703-8; Lamont PJ et al. Hum Mutat. 2014 Jul;35(7):868-79; Komlósi K et al. Neuromuscul Disord. 2014 Feb;24(2):156-61; Oda T et al. Hum Genome Var, 2015 Jul;2:15022; Savarese M et al. Acta Neuropathol Commun. 2014 Sep;2:100; Monies D et al. Am J Hum Genet, 2019 Jun;104:1182-1201; Ganapathy A et al. J Neurol, 2019 Aug;266:1919-1926; Lee HH et al. Genet Test Mol Biomarkers, 2020 Feb;24:99-104; Yu M et al. Orphanet J Rare Dis, 2020 Dec;15:344). One functional study indicated this variant may impair myofilament formation (Parker F et al. J Mol Biol, 2018 May;430:1459-1478). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis (Choi Y et al. PLoS ONE. 2012; 7(10):e46688). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the majority of available evidence to date, this variant is likely to be pathogenic for MYH7-related skeletal myopathy; however, its clinical significance for MYH7-related cardiomyopathy is uncertain. -
Abnormality of the musculature Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at